These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 20171419)

  • 1. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
    Tu HA; Bos JH; Woerdenbag HJ; Visser ST; Wilschut JC; van Assen S; de Jong-van den Berg LT; Postma MJ
    Clin Ther; 2010 Jan; 32(1):133-44. PubMed ID: 20171419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population.
    Jung CW; Tan J; Tan N; Kuo MN; Ashok A; Eells SJ; Miller LG
    J Gastroenterol Hepatol; 2010 Feb; 25(2):369-75. PubMed ID: 19929923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.
    Idris BI; Brosa M; Richardus JH; Esteban R; Schalm SW; Buti M
    Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):320-6. PubMed ID: 18334876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
    Brooks EA; Lacey LF; Payne SL; Miller DW
    Am J Manag Care; 2001 Jul; 7(7):677-82. PubMed ID: 11464426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
    Kanwal F; Farid M; Martin P; Chen G; Gralnek IM; Dulai GS; Spiegel BM
    Am J Gastroenterol; 2006 Sep; 101(9):2076-89. PubMed ID: 16968510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease.
    Osborn MK; Guest JL; Rimland D
    HIV Med; 2007 Jul; 8(5):271-9. PubMed ID: 17561872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy.
    Han SH; Jing W; Mena E; Li M; Pinsky B; Tang H; Hebden T; Juday T
    J Med Econ; 2012; 15(6):1159-66. PubMed ID: 22780707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of prescription practices and of the rational use of medicines in Niger].
    Mallet HP; Njikam A; Scouflaire SM
    Sante; 2001; 11(3):185-93. PubMed ID: 11641083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of chronic hepatitis B in HIV co-infected patients].
    Massard J; Benhamou Y
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt 2):S20-4. PubMed ID: 18662606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.
    Jonas MM; Little NR; Gardner SD;
    J Viral Hepat; 2008 Jan; 15(1):20-7. PubMed ID: 18088241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
    Gaglio PJ; Sterling R; Daniels E; Tedaldi E;
    Clin Infect Dis; 2007 Sep; 45(5):618-23. PubMed ID: 17682998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
    Sims KA; Woodland AM
    Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.
    LaVange LM; Silverman HA
    Natl Med Care Util Expend Surv B; 1987 Apr; (12):1-43. PubMed ID: 10313516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.